Sofinnova, Polaris lead CHF 54m series-A for Noema
Sofinnova Partners and Polaris Partners have co-led a CHF 54m series-A round for Noema Pharma, a Swiss clinical-stage company targeting orphan neurological disorders.
More on Early-stage
Gyroscope Therapeutics raises $148m in Forbion-led series C
Series-C round for the gene therapy company is led by Forbion’s Growth Opportunities Fund
OpenOcean and Spintop lead €3.6m series-A for Cambri
Lynda Clarizio, former president of Nielsen US Media, joins the board of directors
ByFounders leads $4.6m seed round for Proper
Other investors include PreSeed Ventures, Prehype, Vaekstfonden and Bjarke Ingels
Claris Ventures leads £15.2m series-B for NeoPhore
2Invest, 3B Future Health Fund, Astellas Venture Management and CRT Pioneer Fund also take part in the round
Latest News
Searchlight hires new global head of value creation
Amanda Good joins from Hg as partner; she has prior experience with Bain & Company
IK closes third small-cap fund on €1.2bn hard-cap
New fund is more than double the size of its €550m predecessor, IK Small Cap II Fund, which is now almost fully invested
Lansdowne et al. in $120m round for TechMet
Company intends to launch a new round of funding later this year, with the goal of raising around $250m
Muzinich holds third close for second European debt fund
Private debt fund focuses on lower-mid-market companies; its predecessor closed on €706.5m in 2018